HIMS Stock Plunges After FDA Panel Rejects Key Peptide for Compounding
On July 24, 2026, Hims & Hers Health (HIMS) stock fell sharply after an FDA advisory panel voted against adding emideltide to the agency's 503A Bulks List, which governs substances pharmacies can use for custom peptide compounding. The panel cited insufficient safety data, potential manufacturing inconsistencies, and lack of superior efficacy over approved alternatives. While the recommendation is non-binding, the FDA typically follows panel guidance. This decision threatens one of Hims & Hers' fastest-growing, high-margin revenue streams in personalized compounded therapies, particularly for weight-loss and wellness treatments. The stock broke through its 50-day moving average, signaling potential further bearish momentum. Wall Street had a consensus Hold rating with a ~$30 price target before the news, but analysts are expected to issue downward revisions. The setback raises regulatory uncertainty around the company's compounding strategy and may slow future product expansion.
Editorial responsibility
- No named human review is recorded for this page.
- Reports are grouped by semantic similarity and deterministic rules. Language models may assist titles, summaries, translation and cross-source analysis; the page itself is projected from evidence records.
- Current automated evidence projection